BioXcel Therapeutics Inc (BTAI) Expected to Announce Earnings of -$0.48 Per Share

Brokerages forecast that BioXcel Therapeutics Inc (NASDAQ:BTAI) will announce earnings per share of ($0.48) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for BioXcel Therapeutics’ earnings. BioXcel Therapeutics reported earnings per share of ($0.37) in the same quarter last year, which would indicate a negative year-over-year growth rate of 29.7%. The company is expected to announce its next quarterly earnings results on Monday, May 13th.

On average, analysts expect that BioXcel Therapeutics will report full year earnings of ($2.21) per share for the current financial year. For the next fiscal year, analysts expect that the firm will post earnings of ($3.01) per share. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for BioXcel Therapeutics.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its earnings results on Thursday, March 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.13).

Several equities analysts recently weighed in on BTAI shares. HC Wainwright set a $25.00 price target on BioXcel Therapeutics and gave the company a “buy” rating in a research note on Tuesday, March 26th. Zacks Investment Research lowered BioXcel Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 10th. Canaccord Genuity set a $21.00 price target on BioXcel Therapeutics and gave the company a “buy” rating in a research note on Friday, March 8th. Finally, ValuEngine upgraded BioXcel Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday.

NASDAQ BTAI opened at $10.56 on Friday. The stock has a market cap of $159.16 million and a price-to-earnings ratio of -8.00. BioXcel Therapeutics has a fifty-two week low of $2.41 and a fifty-two week high of $14.79.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

Featured Story: What is a back-end load?

Get a free copy of the Zacks research report on BioXcel Therapeutics (BTAI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.